menu
    • menu
    [{"orgOrder":0,"company":"Sotio","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"SOT112","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Synaffix","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ Synaffix"},{"orgOrder":0,"company":"Sotio","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2022","type":"Agreement","leadProduct":"SOT106","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ LegoChem Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ LegoChem Biosciences"},{"orgOrder":0,"company":"Sotio","sponsor":"PPF Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ PPF Group","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ PPF Group"},{"orgOrder":0,"company":"Sotio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Merck & Co"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BOXR1030","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"SOT102","moa":"CLDN18.2","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"SOT102","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SOT201","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Cytune Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Cytune Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Cytune Pharma"},{"orgOrder":0,"company":"Sotio","sponsor":"Cytune Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Cytune Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Cytune Pharma"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"SOT109","moa":"CDH17","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Sotio

    Menu

    Sotio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SOT112

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Synaffix

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            SOTIO Expands ADC Pipeline, Synaffix Pact for Two Bispecific Candidates

                            Details : under the license and option agreement with Synaffix. Sotio will obtain the Synaffix’s technology to develop two bispecific antibody-drug conjugate (ADC) programs.

                            Product Name : SOT112

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            March 13, 2025

                            Lead Product(s) : SOT112

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Synaffix

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SOT109

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SOTIO Unveils Preclinical Data on SOT109 ADC for Colorectal Cancer

                            Details : SOT109 is a next-genaration antibody-drug conjugate targeting Cadherin-17 (CDH17), which is currently being evaluated for the treatment of Colorectal Cancer.

                            Product Name : SOT109

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            March 03, 2025

                            Lead Product(s) : SOT109

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SOT201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SOTIO Doses First Patient In Phase 1 Study Of SOT201 For Solid Tumors

                            Details : SOT201, a next-generation PD-1-targeting immunocytokine monotherapy being investgated for the treatment of advanced solid tumors.

                            Product Name : SOT201

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            May 28, 2024

                            Lead Product(s) : SOT201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BOXR1030

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SOTIO Presents Overview of DUET-01 Phase 1/2 Study at ASCO Annual Meeting

                            Details : BOXR1030 is a metabolically enhanced CAR-T cell therapy which is being investigated in a phase 1/2 study with patients having GPC3-expressing tumors.

                            Product Name : BOXR1030

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            May 23, 2024

                            Lead Product(s) : BOXR1030

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SOT102,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SOTIO Announces First Patients Dosed in Two Combination Arms of CLAUDIO-01 Study Evaluating SOT102 in First-Li...

                            Details : SOT102 is a potent antibody-drug conjugate that combines the clinically-validated target Claudin 18.2 (CLDN18.2) with a powerful toxin to address gastric, pancreatic and other cancers that have very few targeted treatments available.

                            Product Name : SOT102

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            November 10, 2023

                            Lead Product(s) : SOT102,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nanrilkefusp Alpha,Cetuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SOTIO Provides Update on Interim Data from Clinical Trials of Nanrilkefusp Alfa

                            Details : SOT101 (nanrilkefusp alfa) is an IL-15 superagonist that is fused to the sushi+ domain of the IL-15 receptor alpha chain. IL-15 activity increases the number of cytotoxic T cells and NK cells, which shows anti-cancer immune response.

                            Product Name : SOT101

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 13, 2023

                            Lead Product(s) : Nanrilkefusp Alpha,Cetuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nanrilkefusp Alpha,Cetuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sotio Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab

                            Details : SOT101 (nanrilkefusp alfa) is a subcutaneously administered IL-15 superagonist that is fused to the sushi+ domain of the IL-15 receptor alpha chain. IL-15 activity increases the number of cytotoxic T cells and NK cells, which shows anti-cancer immune res...

                            Product Name : SOT101

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 19, 2023

                            Lead Product(s) : Nanrilkefusp Alpha,Cetuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SO-C101,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Interim Data from the Phase 1/1b AURELIO-03 Trial of SOT101 Presented at the AACR 2022 Annual Meeting

                            Details : Data demonstrated that IL-15 superagonist, SOT101 in combination with pembrolizumab was well tolerated and the majority of patients had clinical benefit for patients with advanced metastatic tumors.

                            Product Name : SO-C101

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 04, 2022

                            Lead Product(s) : SO-C101,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SOT106

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : LegoChem Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            SOTIO Exercises Option for Novel Antibody-Drug Conjugate Program under Agreement with LegoChem Biosciences

                            Details : SOT106 is a novel ADC based on SOTIO Biotech’s proprietary antibodies and LCB’s industry-leading ConjuAll™ ADC platform technology with potential best-in class efficacy, safety and tolerability currently in preclinical development against multiple ...

                            Product Name : SOT106

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            November 29, 2022

                            Lead Product(s) : SOT106

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : LegoChem Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed

                            Sotio

                            Czech Republic arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SO-C101,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SOTIO to Present the AURELIO-04 Phase 2 Study Design and Findings from BOXR Research at the SITC Annual Meetin...

                            Details : SOT101 (formerly SO-C101) (RLI-15) is a subcutaneously-administered IL-15 superagonist that is fused to the IL-15α chain receptor. SOT101 is designed to selectively bind only to cytotoxic T and NK cells, while avoiding other cell types that are associat...

                            Product Name : SO-C101

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 18, 2022

                            Lead Product(s) : SO-C101,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth